Needham & Company initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Buy. PT $8.00.

The analyst comments: "Regulus ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE